Compare WFG & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFG | TGTX |
|---|---|---|
| Founded | 1955 | 1993 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.9B |
| IPO Year | 2007 | 2008 |
| Metric | WFG | TGTX |
|---|---|---|
| Price | $63.50 | $26.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $89.50 | $50.67 |
| AVG Volume (30 Days) | 205.8K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 2.77 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $5.36 | $48.75 |
| Revenue Next Year | $10.63 | $25.01 |
| P/E Ratio | ★ N/A | $10.15 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $57.34 | $25.37 |
| 52 Week High | $79.22 | $46.48 |
| Indicator | WFG | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 33.88 |
| Support Level | $62.81 | $25.37 |
| Resistance Level | $76.61 | $32.77 |
| Average True Range (ATR) | 1.84 | 1.22 |
| MACD | -0.41 | -0.20 |
| Stochastic Oscillator | 12.37 | 3.49 |
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.